Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydromorphone + ropivacaine is a combination of two pharmaceutical agents used primarily for regional anesthesia and postoperative pain management. Hydromorphone is a potent semisynthetic opioid analgesic that acts as an agonist at the mu-opioid receptor, providing strong analgesia. Ropivacaine is an amide-type local anesthetic that blocks sodium channels in nerve cells, inhibiting nerve impulse conduction and thus producing local or regional anesthesia. The combination is administered via epidural, spinal, caudal, or peripheral nerve block routes to enhance postoperative pain control while potentially reducing the required dose of each agent and minimizing side effects compared to higher doses of single agents alone. This combination has been studied in various surgical settings including cesarean section, breast surgery (e.g., modified radical mastectomy), hemorrhoidectomy, and pediatric surgeries[1][2][3][4][5]. Clinical studies indicate improved analgesic efficacy with this combination versus either drug alone or other opioid/local anesthetic combinations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydromorphone + ropivacaine.